Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T22:41:00.000Z.
Calculation as of: 2026-10-06T22:41:00.000Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 412370d08cb3fb7a3c2e4d636897a8ea9259835d42853a062d33098765049a4f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$374.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$380.37M
Price/FCF Ratio
N/A
TTM Avg
1258.06
3Y Avg
1258.06
5Y Avg
226.77
Market Cap
$369.50M
Price/FCF Ratio
N/A
TTM Avg
25.86
3Y Avg
25.37
5Y Avg
25.37
Market Cap
$359.53M
Price/FCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
Market Cap
$355.43M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canopy Growth Corporation (CGC) | $376.01M | N/A | N/A | N/A | N/A |
| Zura Bio Limited (ZURA)vs › | $376.19M | N/A | N/A | N/A | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | N/A | 1258.06 | 1258.06 | 226.77 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A | 25.86 | 25.37 | 25.37 |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | N/A | 9.15 | 9.15 | 84.80 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 6.69 | 6.69 | 6.69 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 12.15 | 32.60 | 51.28 | 207.97 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
